Zoetis Inc. (ZTS)


Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Beginner level


Historical Valuation Ratios (Summary)

Zoetis Inc., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Price to earnings (P/E) 45.89 39.46 42.08 35.57 28.68 38.90 39.51 39.53 44.09 35.00 33.42 33.79 31.63 35.08 39.58 62.14 62.14
Price to operating profit (P/OP) 35.00 30.23 32.11 27.78 22.59 23.98 23.28 21.51 22.33 21.75 20.64 20.42 18.65 18.87 20.90 28.06 28.09
Price to sales (P/S) 11.00 9.37 9.57 8.35 7.03 7.92 7.88 7.10 7.18 6.40 5.85 5.83 5.31 4.95 5.21 4.87 4.42
Price to book value (P/BV) 25.42 21.53 24.00 21.31 18.74 21.38 22.36 19.72 21.52 16.49 17.11 17.96 17.46 15.25 18.64 20.16 19.72 18.42 20.48 17.82

Based on: 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Zoetis Inc.’s P/E ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Zoetis Inc.’s P/OP ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Zoetis Inc.’s P/S ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Zoetis Inc.’s P/BV ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.

Price to Earnings (P/E)

Zoetis Inc., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
No. shares of common stock outstanding1 474,933,945 476,299,250 477,557,942 478,656,189 478,771,915 480,450,882 481,823,803 483,865,442 485,253,713 487,288,245 489,111,671 490,796,861 491,964,064 493,832,541 495,043,700 496,202,370 497,155,532 497,920,464 498,943,831 499,964,316
Selected Financial Data (US$)
Net income (loss) attributable to Zoetis Inc. (in millions) 384  433  371  312  345  347  384  352  81  298  247  238  154  239  224  204  22  189  (37) 165 
Earnings per share (EPS)2 3.16 3.07 2.88 2.90 2.98 2.42 2.31 2.02 1.78 1.92 1.80 1.74 1.67 1.40 1.29 0.76 0.68 0.00 0.00 0.00
Share price1, 3 144.94 121.03 121.17 103.15 85.54 94.25 91.43 79.90 78.50 67.31 60.00 58.87 52.78 48.95 51.09 47.34 42.37 45.46 48.28 45.56
Valuation Ratio
P/E ratio4 45.89 39.46 42.08 35.57 28.68 38.90 39.51 39.53 44.09 35.00 33.42 33.79 31.63 35.08 39.58 62.14 62.14
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 44.92 53.17 52.98 56.47 136.66 122.73 213.07 220.29 45.00 73.04 50.48 55.16 41.28 29.01 22.87 12.83 14.78 16.66 16.49
AbbVie Inc. 37.29 23.42 21.71 20.60 17.29 22.09 24.91 35.47 22.56 17.16 16.90 16.54 15.75 18.94 18.46 17.01 37.22 54.50 57.23
Allergan PLC 24.13 6.83 6.75 5.60 5.20 23.71 20.21 31.94 32.56
Amgen Inc. 17.07 15.53 14.06 13.30 14.01 55.79 52.69 52.13 64.06 15.67 15.70 15.16 16.03 14.24 17.32 16.55 15.95
Biogen Inc. 9.97 9.43 8.40 9.32 14.79 19.99 25.30 18.66 28.83 19.16 18.17 17.49 15.41 16.60 16.21 16.57 16.67
Bristol-Myers Squibb Co. 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55 23.59 19.40 18.96 20.56 25.80 43.47 76.64 64.22 62.78 63.57 47.75
Eli Lilly & Co. 13.31 13.84 18.38 39.13 249.24 79.88 41.51 37.39 41.29 32.39 33.66 37.12 35.95 33.35 38.32 45.51 36.38
Gilead Sciences Inc. 30.72 13.61 14.26 15.26 57.34 45.72 24.66 22.75 8.24 7.85 6.92 6.83 6.47 6.49 6.50 6.75 9.29 11.58 10.74
Johnson & Johnson 25.99 24.03 21.50 25.68 23.74 243.48 256.64 271.47 268.10 23.75 21.91 20.12 20.08 19.64 22.55 20.29 18.80
Merck & Co. Inc. 22.67 23.07 23.97 33.46 56.97 132.14 96.71 61.63 53.20 33.41 39.83 46.14 30.16 33.87 32.46 31.64 14.26 16.71 15.25
Pfizer Inc. 12.60 16.12 19.69 21.58 10.64 10.66 9.43 9.99 21.39 23.88 27.02 28.10 32.43 30.28 26.41 26.37 25.22 24.38 22.52
Regeneron Pharmaceuticals Inc. 19.86 17.03 15.94 14.56 18.17 21.53 26.96 22.09 28.99 34.90 43.35 47.93 42.64 45.15 61.42 53.53 60.50
Vertex Pharmaceuticals Inc. 52.90 23.44 20.80 20.51 22.59 65.41 108.21 175.96 155.08 193.19 149.56 166.15

Based on: 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

1 Data adjusted for splits and stock dividends.

2 Q4 2019 Calculation
EPS = (Net income (loss) attributable to Zoetis Inc.Q4 2019 + Net income (loss) attributable to Zoetis Inc.Q3 2019 + Net income (loss) attributable to Zoetis Inc.Q2 2019 + Net income (loss) attributable to Zoetis Inc.Q1 2019) ÷ No. shares of common stock outstanding
= (384,000,000 + 433,000,000 + 371,000,000 + 312,000,000) ÷ 474,933,945 = 3.16

3 Closing price as at the filing date of Zoetis Inc.’s Quarterly or Annual Report.

4 Q4 2019 Calculation
P/E ratio = Share price ÷ EPS
= 144.94 ÷ 3.16 = 45.89

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Zoetis Inc.’s P/E ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.

Price to Operating Profit (P/OP)

Zoetis Inc., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
No. shares of common stock outstanding1 474,933,945 476,299,250 477,557,942 478,656,189 478,771,915 480,450,882 481,823,803 483,865,442 485,253,713 487,288,245 489,111,671 490,796,861 491,964,064 493,832,541 495,043,700 496,202,370 497,155,532 497,920,464 498,943,831 499,964,316
Selected Financial Data (US$)
Operating income (in millions) 482  558  504  423  422  453  479  459  497  457  384  368  299  371  377  345  188  300  258 
Operating profit per share2 4.14 4.00 3.77 3.71 3.79 3.93 3.93 3.71 3.52 3.09 2.91 2.88 2.83 2.59 2.44 1.69 1.51 0.00 0.00 0.00
Share price1, 3 144.94 121.03 121.17 103.15 85.54 94.25 91.43 79.90 78.50 67.31 60.00 58.87 52.78 48.95 51.09 47.34 42.37 45.46 48.28 45.56
Valuation Ratio
P/OP ratio4 35.00 30.23 32.11 27.78 22.59 23.98 23.28 21.51 22.33 21.75 20.64 20.42 18.65 18.87 20.90 28.06 28.09
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 34.32 37.50 36.74 36.64 38.12 38.00 39.99 60.88 47.72 41.32 30.85 24.25 18.51 23.04 20.13 19.80 23.39 26.00 24.36
AbbVie Inc. 18.43 13.53 17.93 18.35 12.32 14.01 15.78 19.63 14.77 11.57 11.19 10.49 10.48 12.51 12.44 11.61 20.93 27.81 27.74
Allergan PLC
Amgen Inc. 13.84 12.52 11.35 10.73 11.46 12.13 12.16 11.45 12.71 12.55 12.46 11.99 12.64 11.56 14.06 13.50 13.07
Biogen Inc. 8.34 7.58 6.74 7.43 11.13 10.78 12.80 9.45 13.70 14.01 13.19 12.69 11.08 11.87 11.51 11.89 12.09
Bristol-Myers Squibb Co. 13.50 10.89 13.68 16.16 19.56 27.48 23.10 28.87 24.60 20.23 19.09 19.79 24.47 43.34 64.30 53.18 41.11 40.96 36.31
Eli Lilly & Co. 23.37 23.99 38.43 33.99 37.45 47.62 25.86 39.61 33.07 29.23 32.37 25.63 27.59 30.51 28.95 29.86 33.90 41.35 33.94
Gilead Sciences Inc. 19.07 9.61 10.14 10.15 9.74 9.58 6.83 7.45 6.02 5.82 5.22 5.23 5.08 5.20 5.25 5.50 7.51 9.26 8.67
Johnson & Johnson 19.83 17.23 19.08 20.36 18.34 20.42 18.93 18.18 18.94 18.71 17.29 15.95 16.09 16.59 18.63 17.98 16.50
Merck & Co. Inc. 17.97 18.21 19.17 25.08 25.60 34.95 27.63 22.58 38.37 25.21 30.01 33.62 21.16 24.34 20.90 20.29 24.08 30.02 32.90
Pfizer Inc. 14.64 13.82 15.62 17.19 18.14 17.36 15.05 15.62 16.20 16.11 16.34 16.88 16.63 16.98 15.88 15.52 17.37 17.41 16.13
Regeneron Pharmaceuticals Inc. 19.01 16.21 15.41 14.44 17.53 16.43 18.75 14.23 16.71 23.63 29.60 32.24 28.70 29.64 36.67 30.59 30.74
Vertex Pharmaceuticals Inc. 51.98 64.96 52.36 56.45 74.57 66.84 442.93 331.55 1,018.05 112.83 99.84 2,143.58

Based on: 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

1 Data adjusted for splits and stock dividends.

2 Q4 2019 Calculation
Operating profit per share = (Operating incomeQ4 2019 + Operating incomeQ3 2019 + Operating incomeQ2 2019 + Operating incomeQ1 2019) ÷ No. shares of common stock outstanding
= (482,000,000 + 558,000,000 + 504,000,000 + 423,000,000) ÷ 474,933,945 = 4.14

3 Closing price as at the filing date of Zoetis Inc.’s Quarterly or Annual Report.

4 Q4 2019 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 144.94 ÷ 4.14 = 35.00

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Zoetis Inc.’s P/OP ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.

Price to Sales (P/S)

Zoetis Inc., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
No. shares of common stock outstanding1 474,933,945 476,299,250 477,557,942 478,656,189 478,771,915 480,450,882 481,823,803 483,865,442 485,253,713 487,288,245 489,111,671 490,796,861 491,964,064 493,832,541 495,043,700 496,202,370 497,155,532 497,920,464 498,943,831 499,964,316
Selected Financial Data (US$)
Revenue (in millions) 1,674  1,584  1,547  1,455  1,564  1,480  1,415  1,366  1,460  1,347  1,269  1,231  1,277  1,241  1,208  1,162  1,274  1,214  1,175  1,102 
Sales per share2 13.18 12.91 12.66 12.36 12.17 11.91 11.60 11.25 10.94 10.52 10.26 10.10 9.94 9.89 9.81 9.72 9.58 0.00 0.00 0.00
Share price1, 3 144.94 121.03 121.17 103.15 85.54 94.25 91.43 79.90 78.50 67.31 60.00 58.87 52.78 48.95 51.09 47.34 42.37 45.46 48.28 45.56
Valuation Ratio
P/S ratio4 11.00 9.37 9.57 8.35 7.03 7.92 7.88 7.10 7.18 6.40 5.85 5.83 5.31 4.95 5.21 4.87 4.42
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.72 4.98 4.52 4.37 3.98 3.84 3.57 3.84 3.77 3.62 3.40 3.70 2.73 3.21 2.74 2.78 3.28 3.67 3.40
AbbVie Inc. 3.69 2.96 3.56 3.58 4.06 4.60 5.37 6.67 5.50 4.25 4.07 3.84 3.79 4.38 4.25 3.83 4.78 5.41 5.09
Allergan PLC 3.70 3.34 2.95 2.93 3.32 3.91 3.12 3.40 3.77 5.28 5.43 5.65 5.47 7.11 5.59 7.81 7.22 7.83 9.13
Amgen Inc. 6.03 5.61 5.00 4.78 5.22 5.56 5.65 5.27 5.82 5.85 5.85 5.48 5.65 5.01 5.97 5.60 5.28
Biogen Inc. 4.08 3.57 3.16 3.15 4.87 4.81 5.83 4.39 5.96 5.64 5.11 5.28 4.98 5.65 5.51 5.60 5.49
Bristol-Myers Squibb Co. 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02 4.85 4.40 4.59 4.72 4.70 7.08 7.13 6.07 6.74 6.95 6.68
Eli Lilly & Co. 4.67 4.67 4.80 5.15 4.62 4.34 3.85 3.71 4.11 4.16 4.18 4.18 3.95 4.44 4.13 4.02 4.59 4.78 4.07
Gilead Sciences Inc. 3.76 3.69 3.84 3.84 4.17 4.43 3.52 4.10 3.54 3.42 3.05 3.08 3.13 3.32 3.48 3.80 5.07 6.06 5.65
Johnson & Johnson 4.79 4.16 4.32 4.62 4.45 4.61 4.36 4.29 4.56 5.06 4.93 4.60 4.62 4.37 4.78 4.49 4.13
Merck & Co. Inc. 4.59 4.87 4.67 4.92 4.57 4.29 3.75 3.68 3.80 4.25 4.34 4.54 4.15 4.41 3.80 3.56 3.87 4.09 4.12
Pfizer Inc. 3.85 3.80 4.20 4.49 4.75 4.51 3.89 4.05 4.00 3.80 3.75 3.84 3.82 4.08 3.95 3.76 4.40 4.50 4.21
Regeneron Pharmaceuticals Inc. 5.34 4.79 4.56 5.11 6.62 6.08 6.92 5.20 5.92 8.09 9.56 9.27 7.86 7.61 9.82 8.95 9.38
Vertex Pharmaceuticals Inc. 14.95 13.89 13.34 13.54 15.54 14.96 17.14 16.47 16.42 16.47 18.23 14.60 12.51 11.33 15.62 15.73 20.38

Based on: 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

1 Data adjusted for splits and stock dividends.

2 Q4 2019 Calculation
Sales per share = (RevenueQ4 2019 + RevenueQ3 2019 + RevenueQ2 2019 + RevenueQ1 2019) ÷ No. shares of common stock outstanding
= (1,674,000,000 + 1,584,000,000 + 1,547,000,000 + 1,455,000,000) ÷ 474,933,945 = 13.18

3 Closing price as at the filing date of Zoetis Inc.’s Quarterly or Annual Report.

4 Q4 2019 Calculation
P/S ratio = Share price ÷ Sales per share
= 144.94 ÷ 13.18 = 11.00

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Zoetis Inc.’s P/S ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.

Price to Book Value (P/BV)

Zoetis Inc., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
No. shares of common stock outstanding1 474,933,945 476,299,250 477,557,942 478,656,189 478,771,915 480,450,882 481,823,803 483,865,442 485,253,713 487,288,245 489,111,671 490,796,861 491,964,064 493,832,541 495,043,700 496,202,370 497,155,532 497,920,464 498,943,831 499,964,316
Selected Financial Data (US$)
Total Zoetis Inc. equity (in millions) 2,708  2,678  2,411  2,317  2,185  2,118  1,970  1,960  1,770  1,989  1,715  1,609  1,487  1,585  1,357  1,165  1,068  1,229  1,176  1,278 
Book value per share (BVPS)2 5.70 5.62 5.05 4.84 4.56 4.41 4.09 4.05 3.65 4.08 3.51 3.28 3.02 3.21 2.74 2.35 2.15 2.47 2.36 2.56
Share price1, 3 144.94 121.03 121.17 103.15 85.54 94.25 91.43 79.90 78.50 67.31 60.00 58.87 52.78 48.95 51.09 47.34 42.37 45.46 48.28 45.56
Valuation Ratio
P/BV ratio4 25.42 21.53 24.00 21.31 18.74 21.38 22.36 19.72 21.52 16.49 17.11 17.96 17.46 15.25 18.64 20.16 19.72 18.42 20.48 17.82
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 4.65 4.86 4.49 4.38 3.94 3.72 3.23 3.40 2.95 2.71 2.42 3.76 2.72 3.20 2.70 2.68 3.19 3.27 3.17
AbbVie Inc. 44.74 36.95 22.43 18.89 21.33 21.24 14.80 19.21 21.77 22.17 21.56 20.64 75.48
Allergan PLC 1.00 0.88 0.75 0.71 0.76 0.89 0.69 0.73 0.82 1.06 1.07 1.08 0.82 1.28 1.15 1.54 1.53 1.74 1.66
Amgen Inc. 13.84 11.47 10.37 9.92 9.41 8.56 8.35 7.41 5.02 3.98 4.05 3.91 4.14 3.51 4.27 4.16 3.94 4.38 4.87 4.66
Biogen Inc. 4.40 3.63 3.44 3.15 5.03 4.63 6.13 3.94 5.80 5.19 5.16 5.30 4.70 5.32 5.43 5.93 6.31 5.83 5.61 8.10
Bristol-Myers Squibb Co. 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36 5.66 5.56 8.36 8.38 7.04 7.39 7.52 6.92
Eli Lilly & Co. 31.28 39.03 46.37 12.87 8.58 8.96 6.18 7.33 6.20 6.49 6.43 6.33 5.28 6.25 5.55 5.51 5.94 6.39 5.35
Gilead Sciences Inc. 4.02 3.58 3.83 3.89 3.98 4.66 4.15 5.15 3.85 4.23 4.28 4.88 5.78 6.83 8.42 6.59 9.02 10.69 8.88
Johnson & Johnson 6.61 5.84 5.78 6.39 6.08 5.81 5.60 5.34 5.79 5.08 4.98 4.72 4.72 4.30 4.68 4.34 4.07 3.91 3.90 4.09
Merck & Co. Inc. 7.87 7.82 7.31 7.79 5.88 5.44 4.54 4.30 3.96 4.31 4.35 4.51 3.78 4.01 3.42 3.15 3.37 3.54 3.57
Pfizer Inc. 3.14 3.42 3.84 3.80 3.55 3.44 2.80 2.98 3.45 3.41 3.37 3.40 3.21 3.40 3.19 2.84 3.15 3.24 3.07
Regeneron Pharmaceuticals Inc. 3.79 3.48 3.38 3.74 5.07 4.92 5.97 4.80 5.66 7.37 9.07 9.49 8.58 8.02 11.19 10.54 10.53 17.80 18.04 16.29
Vertex Pharmaceuticals Inc. 10.23 9.57 9.09 9.36 10.68 14.56 16.73 16.56 20.14 21.11 23.25 19.64 18.42 18.42 24.79 21.23 22.38 33.24 38.35 31.53

Based on: 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

1 Data adjusted for splits and stock dividends.

2 Q4 2019 Calculation
BVPS = Total Zoetis Inc. equity ÷ No. shares of common stock outstanding
= 2,708,000,000 ÷ 474,933,945 = 5.70

3 Closing price as at the filing date of Zoetis Inc.’s Quarterly or Annual Report.

4 Q4 2019 Calculation
P/BV ratio = Share price ÷ BVPS
= 144.94 ÷ 5.70 = 25.42

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Zoetis Inc.’s P/BV ratio decreased from Q2 2019 to Q3 2019 but then increased from Q3 2019 to Q4 2019 exceeding Q2 2019 level.